---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-035656"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:28:11.255837+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Axsome CRESCENDO survey: 77% of treated NT1 patients still have cataplexy; 74% cognitive impairment

## Summary
- 77% of treated NT1 patients continue to experience cataplexy attacks despite current therapy.
- 64% have excessive daytime sleepiness (ESS>10); 74% exhibit cognitive impairment (BC-CCI≥5).
- Depression and anxiety reported by 45% and 57% of patients, respectively.
- Survey included 203 adults; top treatments were wake-promoting agents (53%), oxybates (47%), stimulants (42%).
- Axsome plans to present detailed CRESCENDO results at upcoming scientific meetings.

## SEC filing metadata
- accession: 0000950170-24-035656
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024035656/0000950170-24-035656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024035656/axsm-20240325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-035656
- JSON: https://secwatch.observer/filing/0000950170-24-035656.json
- Plain text: https://secwatch.observer/filing/0000950170-24-035656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.